Why Is SELLAS LIFE SCIENCES (SLS) Stock Down Today?
By the Top Tier Newswire AI Desk · August 31, 2026 at 10:54 AM ET · reviewed against 1 wire stories
SELLAS LIFE SCIENCES (SLS) is down -14.42% in the latest session. Our newswire has captured 1 story on SLS across 1 source in the last 36 hours, with AI sentiment reading bearish (avg 38/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
SLS stock is moving today after opening with a 2.6% gap up from Friday’s close of $13.21. The stock briefly climbed to a session high of $13.88 before retreating to $13.13 in early afternoon trading. The move follows a period of volatility and uncertainty over the company’s AML drug candidate and the upcoming release of pivotal trial data.
What Happened
On Monday, Sellas Life Sciences CEO Angelos Stergiou posted on LinkedIn that the company will let the data from its pivotal AML trial "speak for itself" as the REGAL catalyst nears. The CEO described the data as "rigorous" and "unblinded," suggesting the results will carry significant weight. This statement came after Friday’s 13.15% drop in SLS shares, which traders attributed to the company’s silence on its AML drug candidate. The recent volatility reflects investor uncertainty and speculation about the trial’s outcome.
What The Data Shows
The stock opened at $13.55, a 2.6% gap up from the prior close, but quickly lost ground, reaching a session low of $13.05. Trading volume of 2.1 million shares so far is below the 3-month average. Over the last 8 sessions, the stock has moved up 15.7%, from $13.10 to $15.15. The 52-week range is $1.39 to $15.88, and the stock has printed 5 fresh 52-week highs and 2 fresh 52-week lows on August 31, 2026. Retail chatter on r/wallstreetbets includes a single post thanking the stock, indicating limited retail engagement.
What To Watch
Investors should continue to monitor the release of data from the pivotal AML trial, which is expected to serve as a key catalyst for the stock. No earnings date is currently scheduled, but coverage breadth and analyst commentary will be important to track as the trial nears.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
SLS · Aug 31 session (5-min) · +0.91% vs prior close · updated 8:57 PM ETAI sentiment, last 36h · averaged over 1 story · 38/100 bearish
The headlines behind the move
Story flow · 1 story on the wire, last 36h · hover or tap a dot for the headline
11h agoTechStock²BEARISH 38General
SELLAS Has $138 Million in Cash, but Its $150 Million ATM Still Shapes the Stock
SELLAS Life Sciences entered the second half of 2026 with enough cash to cover roughly four years of operations if its first-half spending pace stayed unchanged. That makes near-term funding pressure look modest—but it does not make dilution irrelevant. The company had $138.3 million of cash at June 30, while its latest Form 10-Q showed…
Frequently asked questions
Why is SLS stock down today?
SELLAS LIFE SCIENCES (SLS) is down -14.42% in the latest session. Our newswire has captured 1 story on SLS across 1 source in the last 36 hours, with AI sentiment reading bearish (avg 38/100). The most recent driver: "SELLAS Has $138 Million in Cash, but Its $150 Million ATM Still Shapes the Stock" (TechStock²).
Is SLS a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of SLS coverage reads 38/100 over 1 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →